[1]
Kikushige Y. Pathogenesis of chronic lymphocytic leukemia and the development of novel therapeutic strategies. Journal of clinical and experimental hematopathology : JCEH. 2020 Dec 15:60(4):146-158. doi: 10.3960/jslrt.20036. Epub 2020 Nov 4
[PubMed PMID: 33148933]
[2]
Hallek M. Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment. American journal of hematology. 2019 Nov:94(11):1266-1287. doi: 10.1002/ajh.25595. Epub 2019 Oct 4
[PubMed PMID: 31364186]
[3]
Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA: a cancer journal for clinicians. 2022 Jan:72(1):7-33. doi: 10.3322/caac.21708. Epub 2022 Jan 12
[PubMed PMID: 35020204]
[4]
Zhang S, Kipps TJ. The pathogenesis of chronic lymphocytic leukemia. Annual review of pathology. 2014:9():103-18. doi: 10.1146/annurev-pathol-020712-163955. Epub 2013 Aug 26
[PubMed PMID: 23987584]
[5]
Law PJ, Berndt SI, Speedy HE, Camp NJ, Sava GP, Skibola CF, Holroyd A, Joseph V, Sunter NJ, Nieters A, Bea S, Monnereau A, Martin-Garcia D, Goldin LR, Clot G, Teras LR, Quintela I, Birmann BM, Jayne S, Cozen W, Majid A, Smedby KE, Lan Q, Dearden C, Brooks-Wilson AR, Hall AG, Purdue MP, Mainou-Fowler T, Vajdic CM, Jackson GH, Cocco P, Marr H, Zhang Y, Zheng T, Giles GG, Lawrence C, Call TG, Liebow M, Melbye M, Glimelius B, Mansouri L, Glenn M, Curtin K, Diver WR, Link BK, Conde L, Bracci PM, Holly EA, Jackson RD, Tinker LF, Benavente Y, Boffetta P, Brennan P, Maynadie M, McKay J, Albanes D, Weinstein S, Wang Z, Caporaso NE, Morton LM, Severson RK, Riboli E, Vineis P, Vermeulen RC, Southey MC, Milne RL, Clavel J, Topka S, Spinelli JJ, Kraft P, Ennas MG, Summerfield G, Ferri GM, Harris RJ, Miligi L, Pettitt AR, North KE, Allsup DJ, Fraumeni JF, Bailey JR, Offit K, Pratt G, Hjalgrim H, Pepper C, Chanock SJ, Fegan C, Rosenquist R, de Sanjose S, Carracedo A, Dyer MJ, Catovsky D, Campo E, Cerhan JR, Allan JM, Rothman N, Houlston R, Slager S. Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia. Nature communications. 2017 Feb 6:8():14175. doi: 10.1038/ncomms14175. Epub 2017 Feb 6
[PubMed PMID: 28165464]
[6]
Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004 Sep 15:104(6):1850-4
[PubMed PMID: 15161669]
[7]
Hernández JA, Land KJ, McKenna RW. Leukemias, myeloma, and other lymphoreticular neoplasms. Cancer. 1995 Jan 1:75(1 Suppl):381-94
[PubMed PMID: 8001009]
[8]
Speedy HE, Beekman R, Chapaprieta V, Orlando G, Law PJ, Martín-García D, Gutiérrez-Abril J, Catovsky D, Beà S, Clot G, Puiggròs M, Torrents D, Puente XS, Allan JM, López-Otín C, Campo E, Houlston RS, Martín-Subero JI. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nature communications. 2019 Aug 9:10(1):3615. doi: 10.1038/s41467-019-11582-2. Epub 2019 Aug 9
[PubMed PMID: 31399598]
[9]
Kipps TJ, Stevenson FK, Wu CJ, Croce CM, Packham G, Wierda WG, O'Brien S, Gribben J, Rai K. Chronic lymphocytic leukaemia. Nature reviews. Disease primers. 2017 Jan 19:3():16096. doi: 10.1038/nrdp.2016.96. Epub 2017 Jan 19
[PubMed PMID: 28102226]
[10]
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. The New England journal of medicine. 2000 Jul 13:343(2):78-85
[PubMed PMID: 10891514]
[11]
Baumann Kreuziger LM, Tarchand G, Morrison VA. The impact of Agent Orange exposure on presentation and prognosis of patients with chronic lymphocytic leukemia. Leukemia & lymphoma. 2014 Jan:55(1):63-6. doi: 10.3109/10428194.2013.794267. Epub 2013 May 15
[PubMed PMID: 23573826]
[12]
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, Dicker DJ, Chimed-Orchir O, Dandona R, Dandona L, Fleming T, Forouzanfar MH, Hancock J, Hay RJ, Hunter-Merrill R, Huynh C, Hosgood HD, Johnson CO, Jonas JB, Khubchandani J, Kumar GA, Kutz M, Lan Q, Larson HJ, Liang X, Lim SS, Lopez AD, MacIntyre MF, Marczak L, Marquez N, Mokdad AH, Pinho C, Pourmalek F, Salomon JA, Sanabria JR, Sandar L, Sartorius B, Schwartz SM, Shackelford KA, Shibuya K, Stanaway J, Steiner C, Sun J, Takahashi K, Vollset SE, Vos T, Wagner JA, Wang H, Westerman R, Zeeb H, Zoeckler L, Abd-Allah F, Ahmed MB, Alabed S, Alam NK, Aldhahri SF, Alem G, Alemayohu MA, Ali R, Al-Raddadi R, Amare A, Amoako Y, Artaman A, Asayesh H, Atnafu N, Awasthi A, Saleem HB, Barac A, Bedi N, Bensenor I, Berhane A, Bernabé E, Betsu B, Binagwaho A, Boneya D, Campos-Nonato I, Castañeda-Orjuela C, Catalá-López F, Chiang P, Chibueze C, Chitheer A, Choi JY, Cowie B, Damtew S, das Neves J, Dey S, Dharmaratne S, Dhillon P, Ding E, Driscoll T, Ekwueme D, Endries AY, Farvid M, Farzadfar F, Fernandes J, Fischer F, G/Hiwot TT, Gebru A, Gopalani S, Hailu A, Horino M, Horita N, Husseini A, Huybrechts I, Inoue M, Islami F, Jakovljevic M, James S, Javanbakht M, Jee SH, Kasaeian A, Kedir MS, Khader YS, Khang YH, Kim D, Leigh J, Linn S, Lunevicius R, El Razek HMA, Malekzadeh R, Malta DC, Marcenes W, Markos D, Melaku YA, Meles KG, Mendoza W, Mengiste DT, Meretoja TJ, Miller TR, Mohammad KA, Mohammadi A, Mohammed S, Moradi-Lakeh M, Nagel G, Nand D, Le Nguyen Q, Nolte S, Ogbo FA, Oladimeji KE, Oren E, Pa M, Park EK, Pereira DM, Plass D, Qorbani M, Radfar A, Rafay A, Rahman M, Rana SM, Søreide K, Satpathy M, Sawhney M, Sepanlou SG, Shaikh MA, She J, Shiue I, Shore HR, Shrime MG, So S, Soneji S, Stathopoulou V, Stroumpoulis K, Sufiyan MB, Sykes BL, Tabarés-Seisdedos R, Tadese F, Tedla BA, Tessema GA, Thakur JS, Tran BX, Ukwaja KN, Uzochukwu BSC, Vlassov VV, Weiderpass E, Wubshet Terefe M, Yebyo HG, Yimam HH, Yonemoto N, Younis MZ, Yu C, Zaidi Z, Zaki MES, Zenebe ZM, Murray CJL, Naghavi M. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic Analysis for the Global Burden of Disease Study. JAMA oncology. 2017 Apr 1:3(4):524-548. doi: 10.1001/jamaoncol.2016.5688. Epub
[PubMed PMID: 27918777]
Level 1 (high-level) evidence
[13]
Wu SJ, Huang SY, Lin CT, Lin YJ, Chang CJ, Tien HF. The incidence of chronic lymphocytic leukemia in Taiwan, 1986-2005: a distinct increasing trend with birth-cohort effect. Blood. 2010 Nov 25:116(22):4430-5. doi: 10.1182/blood-2010-05-285221. Epub 2010 Aug 16
[PubMed PMID: 20713960]
[14]
Miranda-Filho A, Piñeros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. The Lancet. Haematology. 2018 Jan:5(1):e14-e24. doi: 10.1016/S2352-3026(17)30232-6. Epub
[PubMed PMID: 29304322]
Level 2 (mid-level) evidence
[15]
Fleming AF. The epidemiology of lymphomas and leukaemias in Africa--an overview. Leukemia research. 1985:9(6):735-40
[PubMed PMID: 2989624]
Level 3 (low-level) evidence
[16]
Oloo AJ, Ogada TA. Chronic lymphocytic leukaemia (CLL): clinical study at Kenyatta National Hospital (KNH). East African medical journal. 1984 Nov:61(11):797-801
[PubMed PMID: 6535701]
[17]
Sant M, Allemani C, Tereanu C, De Angelis R, Capocaccia R, Visser O, Marcos-Gragera R, Maynadié M, Simonetti A, Lutz JM, Berrino F, HAEMACARE Working Group. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010 Nov 11:116(19):3724-34. doi: 10.1182/blood-2010-05-282632. Epub 2010 Jul 27
[PubMed PMID: 20664057]
[18]
Smith A, Howell D, Patmore R, Jack A, Roman E. Incidence of haematological malignancy by sub-type: a report from the Haematological Malignancy Research Network. British journal of cancer. 2011 Nov 22:105(11):1684-92. doi: 10.1038/bjc.2011.450. Epub 2011 Nov 1
[PubMed PMID: 22045184]
[19]
Yamamoto JF, Goodman MT. Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997-2002. Cancer causes & control : CCC. 2008 May:19(4):379-90
[PubMed PMID: 18064533]
[20]
Strati P, Shanafelt TD. Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification. Blood. 2015 Jul 23:126(4):454-62. doi: 10.1182/blood-2015-02-585059. Epub 2015 Jun 11
[PubMed PMID: 26065657]
[21]
Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, Aldler H, Rattan S, Keating M, Rai K, Rassenti L, Kipps T, Negrini M, Bullrich F, Croce CM. Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proceedings of the National Academy of Sciences of the United States of America. 2002 Nov 26:99(24):15524-9
[PubMed PMID: 12434020]
[22]
Hockenbery D, Nuñez G, Milliman C, Schreiber RD, Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 1990 Nov 22:348(6299):334-6
[PubMed PMID: 2250705]
[23]
Tsagiopoulou M, Chapaprieta V, Duran-Ferrer M, Moysiadis T, Psomopoulos F, Kollia P, Papakonstantinou N, Campo E, Stamatopoulos K, Martin-Subero JI. Chronic lymphocytic leukemias with trisomy 12 show a distinct DNA methylation profile linked to altered chromatin activation. Haematologica. 2020 Dec 1:105(12):2864-2867. doi: 10.3324/haematol.2019.240721. Epub 2020 Dec 1
[PubMed PMID: 33256389]
[24]
Ambrose M, Gatti RA. Pathogenesis of ataxia-telangiectasia: the next generation of ATM functions. Blood. 2013 May 16:121(20):4036-45. doi: 10.1182/blood-2012-09-456897. Epub 2013 Feb 25
[PubMed PMID: 23440242]
[25]
Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer research. 1991 Dec 1:51(23 Pt 1):6304-11
[PubMed PMID: 1933891]
[26]
Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proceedings of the National Academy of Sciences of the United States of America. 1992 Aug 15:89(16):7491-5
[PubMed PMID: 1323840]
[27]
Nadeu F, Delgado J, Royo C, Baumann T, Stankovic T, Pinyol M, Jares P, Navarro A, Martín-García D, Beà S, Salaverria I, Oldreive C, Aymerich M, Suárez-Cisneros H, Rozman M, Villamor N, Colomer D, López-Guillermo A, González M, Alcoceba M, Terol MJ, Colado E, Puente XS, López-Otín C, Enjuanes A, Campo E. Clinical impact of clonal and subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM mutations in chronic lymphocytic leukemia. Blood. 2016 Apr 28:127(17):2122-30. doi: 10.1182/blood-2015-07-659144. Epub 2016 Feb 2
[PubMed PMID: 26837699]
[28]
Wu CJ. CLL clonal heterogeneity: an ecology of competing subpopulations. Blood. 2012 Nov 15:120(20):4117-8. doi: 10.1182/blood-2012-09-452805. Epub
[PubMed PMID: 23160186]
[29]
Puente XS, Beà S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martín-Subero JI, Munar M, Rubio-Pérez C, Jares P, Aymerich M, Baumann T, Beekman R, Belver L, Carrio A, Castellano G, Clot G, Colado E, Colomer D, Costa D, Delgado J, Enjuanes A, Estivill X, Ferrando AA, Gelpí JL, González B, González S, González M, Gut M, Hernández-Rivas JM, López-Guerra M, Martín-García D, Navarro A, Nicolás P, Orozco M, Payer ÁR, Pinyol M, Pisano DG, Puente DA, Queirós AC, Quesada V, Romeo-Casabona CM, Royo C, Royo R, Rozman M, Russiñol N, Salaverría I, Stamatopoulos K, Stunnenberg HG, Tamborero D, Terol MJ, Valencia A, López-Bigas N, Torrents D, Gut I, López-Guillermo A, López-Otín C, Campo E. Non-coding recurrent mutations in chronic lymphocytic leukaemia. Nature. 2015 Oct 22:526(7574):519-24. doi: 10.1038/nature14666. Epub 2015 Jul 22
[PubMed PMID: 26200345]
[30]
Landau DA, Tausch E, Taylor-Weiner AN, Stewart C, Reiter JG, Bahlo J, Kluth S, Bozic I, Lawrence M, Böttcher S, Carter SL, Cibulskis K, Mertens D, Sougnez CL, Rosenberg M, Hess JM, Edelmann J, Kless S, Kneba M, Ritgen M, Fink A, Fischer K, Gabriel S, Lander ES, Nowak MA, Döhner H, Hallek M, Neuberg D, Getz G, Stilgenbauer S, Wu CJ. Mutations driving CLL and their evolution in progression and relapse. Nature. 2015 Oct 22:526(7574):525-30. doi: 10.1038/nature15395. Epub 2015 Oct 14
[PubMed PMID: 26466571]
[31]
Rossi D, Khiabanian H, Spina V, Ciardullo C, Bruscaggin A, Famà R, Rasi S, Monti S, Deambrogi C, De Paoli L, Wang J, Gattei V, Guarini A, Foà R, Rabadan R, Gaidano G. Clinical impact of small TP53 mutated subclones in chronic lymphocytic leukemia. Blood. 2014 Apr 3:123(14):2139-47. doi: 10.1182/blood-2013-11-539726. Epub 2014 Feb 5
[PubMed PMID: 24501221]
[32]
Rossi D, Rasi S, Fabbri G, Spina V, Fangazio M, Forconi F, Marasca R, Laurenti L, Bruscaggin A, Cerri M, Monti S, Cresta S, Famà R, De Paoli L, Bulian P, Gattei V, Guarini A, Deaglio S, Capello D, Rabadan R, Pasqualucci L, Dalla-Favera R, Foà R, Gaidano G. Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia. Blood. 2012 Jan 12:119(2):521-9. doi: 10.1182/blood-2011-09-379966. Epub 2011 Nov 10
[PubMed PMID: 22077063]
[33]
Wang L, Lawrence MS, Wan Y, Stojanov P, Sougnez C, Stevenson K, Werner L, Sivachenko A, DeLuca DS, Zhang L, Zhang W, Vartanov AR, Fernandes SM, Goldstein NR, Folco EG, Cibulskis K, Tesar B, Sievers QL, Shefler E, Gabriel S, Hacohen N, Reed R, Meyerson M, Golub TR, Lander ES, Neuberg D, Brown JR, Getz G, Wu CJ. SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. The New England journal of medicine. 2011 Dec 29:365(26):2497-506. doi: 10.1056/NEJMoa1109016. Epub 2011 Dec 12
[PubMed PMID: 22150006]
[34]
Oscier DG, Rose-Zerilli MJ, Winkelmann N, Gonzalez de Castro D, Gomez B, Forster J, Parker H, Parker A, Gardiner A, Collins A, Else M, Cross NC, Catovsky D, Strefford JC. The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial. Blood. 2013 Jan 17:121(3):468-75. doi: 10.1182/blood-2012-05-429282. Epub 2012 Oct 18
[PubMed PMID: 23086750]
[35]
Fulci V, Chiaretti S, Goldoni M, Azzalin G, Carucci N, Tavolaro S, Castellano L, Magrelli A, Citarella F, Messina M, Maggio R, Peragine N, Santangelo S, Mauro FR, Landgraf P, Tuschl T, Weir DB, Chien M, Russo JJ, Ju J, Sheridan R, Sander C, Zavolan M, Guarini A, Foà R, Macino G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood. 2007 Jun 1:109(11):4944-51
[PubMed PMID: 17327404]
[36]
Ferrajoli A, Shanafelt TD, Ivan C, Shimizu M, Rabe KG, Nouraee N, Ikuo M, Ghosh AK, Lerner S, Rassenti LZ, Xiao L, Hu J, Reuben JM, Calin S, You MJ, Manning JT, Wierda WG, Estrov Z, O'Brien S, Kipps TJ, Keating MJ, Kay NE, Calin GA. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and patients with B chronic lymphocytic leukemia. Blood. 2013 Sep 12:122(11):1891-9. doi: 10.1182/blood-2013-01-478222. Epub 2013 Jul 2
[PubMed PMID: 23821659]
[37]
Sampath D, Liu C, Vasan K, Sulda M, Puduvalli VK, Wierda WG, Keating MJ. Histone deacetylases mediate the silencing of miR-15a, miR-16, and miR-29b in chronic lymphocytic leukemia. Blood. 2012 Feb 2:119(5):1162-72. doi: 10.1182/blood-2011-05-351510. Epub 2011 Nov 16
[PubMed PMID: 22096249]
[38]
Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer research. 2007 Sep 15:67(18):8433-8
[PubMed PMID: 17823410]
[39]
Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, Smith EN, Messer K, Frazer KA, Kipps TJ. miR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014 Jul 3:124(1):84-95. doi: 10.1182/blood-2013-09-527234. Epub 2014 May 1
[PubMed PMID: 24787006]
[40]
Woyach JA, Johnson AJ, Byrd JC. The B-cell receptor signaling pathway as a therapeutic target in CLL. Blood. 2012 Aug 9:120(6):1175-84. doi: 10.1182/blood-2012-02-362624. Epub 2012 Jun 19
[PubMed PMID: 22715122]
[41]
Delgado J, Nadeu F, Colomer D, Campo E. Chronic lymphocytic leukemia: from molecular pathogenesis to novel therapeutic strategies. Haematologica. 2020 Sep 1:105(9):2205-2217. doi: 10.3324/haematol.2019.236000. Epub 2020 Sep 1
[PubMed PMID: 33054046]
[42]
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, Hillmen P, Keating M, Montserrat E, Chiorazzi N, Stilgenbauer S, Rai KR, Byrd JC, Eichhorst B, O'Brien S, Robak T, Seymour JF, Kipps TJ. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018 Jun 21:131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14
[PubMed PMID: 29540348]
[43]
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug:46(2):219-34
[PubMed PMID: 1139039]
[44]
Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, Jacquillat C, Boivin P, Lesty C, Duault MT, Monconduit M, Belabbes S, Gremy F. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer. 1981 Jul 1:48(1):198-206
[PubMed PMID: 7237385]
[45]
Agnew KL, Ruchlemer R, Catovsky D, Matutes E, Bunker CB. Cutaneous findings in chronic lymphocytic leukaemia. The British journal of dermatology. 2004 Jun:150(6):1129-35
[PubMed PMID: 15214899]
[46]
Lazarian G, Munger M, Quinquenel A, Dilhuydy MS, Veronese L, Luque Paz D, Guièze R, Ledoux-Pilon A, Paillassa J, Merabet F, Vial JP, Bidet A, Waultier Rascalou A, Broseus J, Roos-Weil D, Lavaud A, Molina L, Laribi K, Hivert B, Friedrich C, Carpentier B, Ysebaert L, Van Den Neste E, Willems L, Corby A, Poulain S, Eclache V, Maubec E, Martin A, Feugier P, Delmer A, Baran-Marszak F, Leprêtre S, Cymbalista F. Clinical and biological characteristics of leukemia cutis in chronic lymphocytic leukemia: A study of the French innovative leukemia organization (FILO). American journal of hematology. 2021 Sep 1:96(9):E353-E356. doi: 10.1002/ajh.26274. Epub 2021 Jul 1
[PubMed PMID: 34152612]
[47]
Baer MR, Stein RS, Dessypris EN. Chronic lymphocytic leukemia with hyperleukocytosis. The hyperviscosity syndrome. Cancer. 1985 Dec 15:56(12):2865-9
[PubMed PMID: 4052958]
[48]
Kern W, Bacher U, Schnittger S, Dicker F, Alpermann T, Haferlach T, Haferlach C. Flow cytometric identification of 76 patients with biclonal disease among 5523 patients with chronic lymphocytic leukaemia (B-CLL) and its genetic characterization. British journal of haematology. 2014 Feb:164(4):565-9. doi: 10.1111/bjh.12652. Epub 2013 Nov 14
[PubMed PMID: 24236747]
[49]
Döhner H, Fischer K, Bentz M, Hansen K, Benner A, Cabot G, Diehl D, Schlenk R, Coy J, Stilgenbauer S, Volkmann M, Galle PR, Poustka A, Hunstein W, Lichter P. p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias. Blood. 1995 Mar 15:85(6):1580-9
[PubMed PMID: 7888675]
[50]
el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R, Newcomb EW. p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood. 1993 Dec 1:82(11):3452-9
[PubMed PMID: 8241511]
[51]
Cordone I, Masi S, Mauro FR, Soddu S, Morsilli O, Valentini T, Vegna ML, Guglielmi C, Mancini F, Giuliacci S, Sacchi A, Mandelli F, Foa R. p53 expression in B-cell chronic lymphocytic leukemia: a marker of disease progression and poor prognosis. Blood. 1998 Jun 1:91(11):4342-9
[PubMed PMID: 9596683]
[52]
Papa G, Mauro FR, Anselmo AP, Cimino G, Alimena G, Amadori S, D'Arcangelo E, Giannarelli D, Bosi A, Bellesi G. Acute leukaemia in patients treated for Hodgkin's disease. British journal of haematology. 1984 Sep:58(1):43-52
[PubMed PMID: 6466571]
[53]
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Eckart MJ, Vehling-Kaiser U, Schimke H, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner CM, Bahlo J, Fischer K, Bentz M, Emmerich B, Döhner H, Hallek M, Stilgenbauer S. Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 Dec:31(12):2833-2837. doi: 10.1038/leu.2017.246. Epub 2017 Aug 14
[PubMed PMID: 28804126]
[54]
Herling CD, Cymbalista F, Groß-Ophoff-Müller C, Bahlo J, Robrecht S, Langerbeins P, Fink AM, Al-Sawaf O, Busch R, Porcher R, Cazin B, Dreyfus B, Ibach S, Leprêtre S, Fischer K, Kaiser F, Eichhorst B, Wentner CM, Hoechstetter MA, Döhner H, Leblond V, Kneba M, Letestu R, Böttcher S, Stilgenbauer S, Hallek M, Levy V. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020 Aug:34(8):2038-2050. doi: 10.1038/s41375-020-0747-7. Epub 2020 Feb 18
[PubMed PMID: 32071431]
Level 1 (high-level) evidence
[55]
. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. Journal of the National Cancer Institute. 1999 May 19:91(10):861-8
[PubMed PMID: 10340906]
Level 1 (high-level) evidence
[56]
Condoluci A, Terzi di Bergamo L, Langerbeins P, Hoechstetter MA, Herling CD, De Paoli L, Delgado J, Rabe KG, Gentile M, Doubek M, Mauro FR, Chiodin G, Mattsson M, Bahlo J, Cutrona G, Kotaskova J, Deambrogi C, Smedby KE, Spina V, Bruscaggin A, Wu W, Moia R, Bianchi E, Gerber B, Zucca E, Gillessen S, Ghielmini M, Cavalli F, Stussi G, Hess MA, Baumann TS, Neri A, Ferrarini M, Rosenquist R, Forconi F, Foà R, Pospisilova S, Morabito F, Stilgenbauer S, Döhner H, Parikh SA, Wierda WG, Montserrat E, Gaidano G, Hallek M, Rossi D. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020 May 21:135(21):1859-1869. doi: 10.1182/blood.2019003453. Epub
[PubMed PMID: 32267500]
[57]
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, Robrecht S, Warburton S, Humphrey K, Samoylova O, Liberati AM, Pinilla-Ibarz J, Opat S, Sivcheva L, Le Dû K, Fogliatto LM, Niemann CU, Weinkove R, Robinson S, Kipps TJ, Boettcher S, Tausch E, Humerickhouse R, Eichhorst B, Wendtner CM, Langerak AW, Kreuzer KA, Ritgen M, Goede V, Stilgenbauer S, Mobasher M, Hallek M. Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. The New England journal of medicine. 2019 Jun 6:380(23):2225-2236. doi: 10.1056/NEJMoa1815281. Epub 2019 Jun 4
[PubMed PMID: 31166681]
[58]
Al-Sawaf O, Lilienweiss E, Bahlo J, Robrecht S, Fink AM, Patz M, Tandon M, Jiang Y, Schary W, Ritgen M, Tausch E, Stilgenbauer S, Eichhorst B, Fischer K, Hallek M, Kreuzer KA. High efficacy of venetoclax plus obinutuzumab in patients with complex karyotype and chronic lymphocytic leukemia. Blood. 2020 Mar 12:135(11):866-870. doi: 10.1182/blood.2019003451. Epub
[PubMed PMID: 31990291]
[59]
Al-Sawaf O, Gentile B, Devine J, Zhang C, Sail K, Tandon M, Fink AM, Kutsch N, Wendtner CM, Eichhorst B, Hallek M, Fischer K. Health-related quality of life with fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: Results from the randomized, phase 3 CLL14 trial. American journal of hematology. 2021 Sep 1:96(9):1112-1119. doi: 10.1002/ajh.26260. Epub 2021 Jun 22
[PubMed PMID: 34050972]
Level 2 (mid-level) evidence
[60]
Pepper C, Majid A, Lin TT, Hewamana S, Pratt G, Walewska R, Gesk S, Siebert R, Wagner S, Kennedy B, Miall F, Davis ZA, Tracy I, Gardiner AC, Brennan P, Hills RK, Dyer MJ, Oscier D, Fegan C. Defining the prognosis of early stage chronic lymphocytic leukaemia patients. British journal of haematology. 2012 Feb:156(4):499-507. doi: 10.1111/j.1365-2141.2011.08974.x. Epub 2011 Dec 15
[PubMed PMID: 22171799]
[61]
Melo JV, Catovsky D, Galton DA. The relationship between chronic lymphocytic leukaemia and prolymphocytic leukaemia. I. Clinical and laboratory features of 300 patients and characterization of an intermediate group. British journal of haematology. 1986 Jun:63(2):377-87
[PubMed PMID: 3487341]
[62]
Lampert I, Catovsky D, Marsh GW, Child JA, Galton DA. The histopathology of prolymphocytic leukaemia with particular reference to the spleen: a comparison with chronic lymphocytic leukaemia. Histopathology. 1980 Jan:4(1):3-19
[PubMed PMID: 7353816]
[63]
Catovsky D. Hairy-cell leukaemia and prolymphocytic leukaemia. Clinics in haematology. 1977 Feb:6(1):245-68
[PubMed PMID: 334414]
[64]
Nathwani BN, Anderson JR, Armitage JO, Cavalli F, Diebold J, Drachenberg MR, Harris NL, MacLennan KA, Müller-Hermelink HK, Ullrich FA, Weisenburger DD. Clinical significance of follicular lymphoma with monocytoid B cells. Non-Hodgkin's Lymphoma Classification Project. Human pathology. 1999 Mar:30(3):263-8
[PubMed PMID: 10088543]
[65]
Vitolo U, Ferreri AJ, Montoto S. Lymphoplasmacytic lymphoma-Waldenstrom's macroglobulinemia. Critical reviews in oncology/hematology. 2008 Aug:67(2):172-85. doi: 10.1016/j.critrevonc.2008.03.008. Epub 2008 May 21
[PubMed PMID: 18499469]
[66]
Dimopoulos MA, Kyle RA, Anagnostopoulos A, Treon SP. Diagnosis and management of Waldenstrom's macroglobulinemia. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Mar 1:23(7):1564-77
[PubMed PMID: 15735132]
[67]
DiRaimondo F, Albitar M, Huh Y, O'Brien S, Montillo M, Tedeschi A, Kantarjian H, Lerner S, Giustolisi R, Keating M. The clinical and diagnostic relevance of CD23 expression in the chronic lymphoproliferative disease. Cancer. 2002 Mar 15:94(6):1721-30
[PubMed PMID: 11920534]
[68]
Perry DA, Bast MA, Armitage JO, Weisenburger DD. Diffuse intermediate lymphocytic lymphoma. A clinicopathologic study and comparison with small lymphocytic lymphoma and diffuse small cleaved cell lymphoma. Cancer. 1990 Nov 1:66(9):1995-2000
[PubMed PMID: 2224798]
[69]
Savilo E, Campo E, Mollejo M, Pinyol M, Piris MA, Zukerberg LR, Yang WI, Koelliker DD, Nguyen PL, Harris NL. Absence of cyclin D1 protein expression in splenic marginal zone lymphoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 1998 Jul:11(7):601-6
[PubMed PMID: 9688179]
[70]
Thieblemont C, Felman P, Callet-Bauchu E, Traverse-Glehen A, Salles G, Berger F, Coiffier B. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. The Lancet. Oncology. 2003 Feb:4(2):95-103
[PubMed PMID: 12573351]
[71]
Gruszka-Westwood AM, Matutes E, Coignet LJ, Wotherspoon A, Catovsky D. The incidence of trisomy 3 in splenic lymphoma with villous lymphocytes: a study by FISH. British journal of haematology. 1999 Mar:104(3):600-4
[PubMed PMID: 10086800]
[72]
Isaacson PG, Matutes E, Burke M, Catovsky D. The histopathology of splenic lymphoma with villous lymphocytes. Blood. 1994 Dec 1:84(11):3828-34
[PubMed PMID: 7949139]
[73]
Langerbeins P, Zhang C, Robrecht S, Cramer P, Fürstenau M, Al-Sawaf O, von Tresckow J, Fink AM, Kreuzer KA, Vehling-Kaiser U, Tausch E, Müller L, Eckart MJ, Schlag R, Freier W, Gaska T, Balser C, Reiser M, Stauch M, Wendtner CM, Fischer K, Stilgenbauer S, Eichhorst B, Hallek M. The CLL12 trial: ibrutinib vs placebo in treatment-naïve, early-stage chronic lymphocytic leukemia. Blood. 2022 Jan 13:139(2):177-187. doi: 10.1182/blood.2021010845. Epub
[PubMed PMID: 34758069]
[74]
Moreno C, Hodgson K, Ferrer G, Elena M, Filella X, Pereira A, Baumann T, Montserrat E. Autoimmune cytopenia in chronic lymphocytic leukemia: prevalence, clinical associations, and prognostic significance. Blood. 2010 Dec 2:116(23):4771-6. doi: 10.1182/blood-2010-05-286500. Epub 2010 Aug 24
[PubMed PMID: 20736453]
[75]
Binet JL, Leporrier M, Dighiero G, Charron D, D'Athis P, Vaugier G, Beral HM, Natali JC, Raphael M, Nizet B, Follezou JY. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer. 1977 Aug:40(2):855-64
[PubMed PMID: 890666]
[76]
International CLL-IPI working group. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data. The Lancet. Oncology. 2016 Jun:17(6):779-790. doi: 10.1016/S1470-2045(16)30029-8. Epub 2016 May 13
[PubMed PMID: 27185642]
Level 1 (high-level) evidence
[77]
Hoechstetter MA, Busch R, Eichhorst B, Bühler A, Winkler D, Bahlo J, Robrecht S, Eckart MJ, Vehling-Kaiser U, Jacobs G, Jäger U, Hurtz HJ, Hopfinger G, Hartmann F, Fuss H, Abenhardt W, Blau I, Freier W, Müller L, Goebeler M, Wendtner C, Fischer K, Herling CD, Starck M, Bentz M, Emmerich B, Döhner H, Stilgenbauer S, Hallek M. Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study group. Leukemia. 2020 Apr:34(4):1038-1051. doi: 10.1038/s41375-020-0727-y. Epub 2020 Feb 10
[PubMed PMID: 32042081]
[78]
Morabito F, Tripepi G, Del Poeta G, Mauro FR, Reda G, Sportoletti P, Laurenti L, Coscia M, Herishanu Y, Varettoni M, Murru R, Chiarenza A, Visentin A, Condoluci A, Moia R, Pietrasanta D, Loseto G, Consoli U, Scortechini I, Rossi FM, Zucchetto A, Vigna E, Martino EA, Mendicino F, Botta C, Caracciolo D, Cassin R, D'Arrigo G, Galimberti S, Rago A, Angeletti I, Biagi A, Del Giudice I, Bomben R, Neri A, Fronza G, Cutrona G, Rossi D, Di Raimondo F, Cuneo A, Gaidano G, Polliack A, Trentin L, Foà R, Ferrarini M, Gattei V, Gentile M. Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. American journal of hematology. 2021 May 1:96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24
[PubMed PMID: 33580969]
Level 2 (mid-level) evidence
[79]
Hayes DF. Defining Clinical Utility of Tumor Biomarker Tests: A Clinician's Viewpoint. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Jan 20:39(3):238-248. doi: 10.1200/JCO.20.01572. Epub 2020 Dec 16
[PubMed PMID: 33326253]
[80]
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, Bahlo J, Al-Sawaf O, Ritgen M, Fink AM, Eichhorst B, Kreuzer KA, Tandon M, Humphrey K, Jiang Y, Schary W, Bullinger L, Mertens D, Lurà MP, Kneba M, Döhner H, Fischer K, Hallek M, Stilgenbauer S. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020 Jun 25:135(26):2402-2412. doi: 10.1182/blood.2019004492. Epub
[PubMed PMID: 32206772]
[81]
Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999 Sep 15:94(6):1848-54
[PubMed PMID: 10477713]
[82]
Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood. 1999 Sep 15:94(6):1840-7
[PubMed PMID: 10477712]
[83]
Pflug N, Bahlo J, Shanafelt TD, Eichhorst BF, Bergmann MA, Elter T, Bauer K, Malchau G, Rabe KG, Stilgenbauer S, Döhner H, Jäger U, Eckart MJ, Hopfinger G, Busch R, Fink AM, Wendtner CM, Fischer K, Kay NE, Hallek M. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014 Jul 3:124(1):49-62. doi: 10.1182/blood-2014-02-556399. Epub 2014 May 5
[PubMed PMID: 24797299]
[84]
Tausch E, Close W, Dolnik A, Bloehdorn J, Chyla B, Bullinger L, Döhner H, Mertens D, Stilgenbauer S. Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia. Haematologica. 2019 Sep:104(9):e434-e437. doi: 10.3324/haematol.2019.222588. Epub 2019 Apr 19
[PubMed PMID: 31004028]
[85]
Lucas F, Larkin K, Gregory CT, Orwick S, Doong TJ, Lozanski A, Lozanski G, Misra S, Ngankeu A, Ozer HG, Sampath D, Thangavadivel S, Yilmaz SA, Rogers KA, Byrd JC, Woyach JA, Blachly JS. Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations. Blood. 2020 Jun 11:135(24):2192-2195. doi: 10.1182/blood.2019003722. Epub
[PubMed PMID: 32232486]
[86]
Blombery P, Thompson ER, Nguyen T, Birkinshaw RW, Gong JN, Chen X, McBean M, Thijssen R, Conway T, Anderson MA, Seymour JF, Westerman DA, Czabotar PE, Huang DCS, Roberts AW. Multiple BCL2 mutations cooccurring with Gly101Val emerge in chronic lymphocytic leukemia progression on venetoclax. Blood. 2020 Mar 5:135(10):773-777. doi: 10.1182/blood.2019004205. Epub
[PubMed PMID: 31951646]
[87]
Wierda WG, O'Brien S, Wang X, Faderl S, Ferrajoli A, Do KA, Cortes J, Thomas D, Garcia-Manero G, Koller C, Beran M, Giles F, Ravandi F, Lerner S, Kantarjian H, Keating M. Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia. Blood. 2007 Jun 1:109(11):4679-85
[PubMed PMID: 17299097]
[88]
Molica S, Alberti A. Prognostic value of the lymphocyte doubling time in chronic lymphocytic leukemia. Cancer. 1987 Dec 1:60(11):2712-6
[PubMed PMID: 3677006]
[89]
Patterson TF, Thompson GR 3rd, Denning DW, Fishman JA, Hadley S, Herbrecht R, Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Practice Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2016 Aug 15:63(4):e1-e60. doi: 10.1093/cid/ciw326. Epub 2016 Jun 29
[PubMed PMID: 27365388]
Level 1 (high-level) evidence
[90]
Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clinical microbiology reviews. 2004 Oct:17(4):770-82, table of contents
[PubMed PMID: 15489347]
[91]
Helweg-Larsen J, Tsolaki AG, Miller RF, Lundgren B, Wakefield AE. Clusters of Pneumocystis carinii pneumonia: analysis of person-to-person transmission by genotyping. QJM : monthly journal of the Association of Physicians. 1998 Dec:91(12):813-20
[PubMed PMID: 10024946]
[92]
Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2009 Mar 15:48(6):772-86. doi: 10.1086/597089. Epub
[PubMed PMID: 19207081]
[93]
Dührsen U, Augener W, Zwingers T, Brittinger G. Spectrum and frequency of autoimmune derangements in lymphoproliferative disorders: analysis of 637 cases and comparison with myeloproliferative diseases. British journal of haematology. 1987 Oct:67(2):235-9
[PubMed PMID: 3499930]
Level 3 (low-level) evidence
[94]
Mauro FR, Foa R, Cerretti R, Giannarelli D, Coluzzi S, Mandelli F, Girelli G. Autoimmune hemolytic anemia in chronic lymphocytic leukemia: clinical, therapeutic, and prognostic features. Blood. 2000 May 1:95(9):2786-92
[PubMed PMID: 10779422]
[95]
Diehl LF, Ketchum LH. Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Seminars in oncology. 1998 Feb:25(1):80-97
[PubMed PMID: 9482530]
[96]
Visco C, Ruggeri M, Laura Evangelista M, Stasi R, Zanotti R, Giaretta I, Ambrosetti A, Madeo D, Pizzolo G, Rodeghiero F. Impact of immune thrombocytopenia on the clinical course of chronic lymphocytic leukemia. Blood. 2008 Feb 1:111(3):1110-6
[PubMed PMID: 17986663]
[97]
Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016 Feb 25:127(8):1064-7. doi: 10.1182/blood-2015-12-686873. Epub 2015 Dec 23
[PubMed PMID: 26702066]
[98]
Solomon BM, Rabe KG, Slager SL, Brewer JD, Cerhan JR, Shanafelt TD. Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2013 Mar 1:31(7):930-7. doi: 10.1200/JCO.2012.43.4449. Epub 2013 Jan 22
[PubMed PMID: 23341508]
[99]
Ben-Dali Y, Hleuhel MH, da Cunha-Bang C, Brieghel C, Poulsen CB, Clasen-Linde E, Bentzen HHN, Frederiksen H, Christiansen I, Nielsen LH, Enggaard L, Helleberg M, Clausen M, Frederiksen M, Pedersen RS, Niemann CU, Andersen MA. Richter's transformation in patients with chronic lymphocytic leukaemia: a Nationwide Epidemiological Study. Leukemia & lymphoma. 2020 Jun:61(6):1435-1444. doi: 10.1080/10428194.2020.1719092. Epub 2020 Feb 7
[PubMed PMID: 32031030]
Level 2 (mid-level) evidence
[100]
Tsimberidou AM, Keating MJ. Richter syndrome: biology, incidence, and therapeutic strategies. Cancer. 2005 Jan 15:103(2):216-28
[PubMed PMID: 15578683]